Newest addition to Physicians' Desk Reference collection will be available in bookstores at end of March, Medical Economics says. Reference includes detailed monographs on nearly 300 supplements in categories such as vitamins, metabolites, hormones, proteins, minerals, lipids and probiotics. While the current PDR for Nonprescription Drugs & Dietary Supplements contains several paragraphs of manufacturer-supplied information on supplements, new publication offers multiple pages per monograph of evidence-based information taken from clinical research and medical literature
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.
Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.
Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.
